Core Insights - Bristol-Myers Squibb (BMY) has shown strong performance, finishing 2025 with a market capitalization of $110 billion and an 18% return including dividends since the third quarter [1] Group 1: Company Performance - The stock has returned a solid 18% since the third quarter, indicating positive market sentiment and investor confidence in the company's future prospects [1]

Core Insights - MLP units have significantly underperformed compared to the S&P 500, with the S&P 500 SPDR ETF (SPY) increasing by 17% including dividends through Thanksgiving, while MLP units lag behind [1] Performance Comparison - The S&P 500 SPDR ETF (SPY) has shown a 17% increase through Thanksgiving, indicating strong market performance [1] Investment Context - The article highlights the disparity in performance between MLP units and broader market indices, suggesting potential implications for investors considering MLP investments [1]